Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes
Public ClinicalTrials.gov record NCT00348374. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3b, Randomized, Open-Label, Parallel Group, Multicenter Trial Assessing The Efficacy Of Exubera Vs. Lispro Introduced Into A Lantus Based Regimen In Suboptimally Controlled Patients With Type 2 Diabetes Mellitus
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The current trial will examine the efficacy and safety of Exubera administered as a mealtime insulin compared to lispro, when added to an existing regimen of basal insulin glargine + or = Oral Agents (OAs). Dose titrations will be provided which should allow a large proportion of subjects to reach target glycosylated hemoglobin (A1C) levels.
Study identification
- NCT ID
- NCT00348374
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 191 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2006
- Primary completion
- Jul 31, 2008
- Completion
- Jul 31, 2008
- Last update posted
- Mar 15, 2010
2006 – 2008
United States locations
- U.S. sites
- 62
- U.S. states
- 33
- U.S. cities
- 58
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Birmingham | Alabama | 35294-307 | — |
| Pfizer Investigational Site | Mobile | Alabama | 36608 | — |
| Pfizer Investigational Site | Phoenix | Arizona | 85006-2850 | — |
| Pfizer Investigational Site | Malvern | Arkansas | 72104 | — |
| Pfizer Investigational Site | Foot Hill Ranch | California | 92610 | — |
| Pfizer Investigational Site | Fresno | California | 93720 | — |
| Pfizer Investigational Site | Greenbrae | California | 94904 | — |
| Pfizer Investigational Site | Los Gatos | California | 95032-3739 | — |
| Pfizer Investigational Site | San Diego | California | 92120 | — |
| Pfizer Investigational Site | San Mateo | California | 94401-3805 | — |
| Pfizer Investigational Site | Tustin | California | 92780 | — |
| Pfizer Investigational Site | Denver | Colorado | 80209 | — |
| Pfizer Investigational Site | New Britain | Connecticut | 06050 | — |
| Pfizer Investigational Site | Washington D.C. | District of Columbia | 20010-2934 | — |
| Pfizer Investigational Site | Jacksonville | Florida | 32205 | — |
| Pfizer Investigational Site | Jacksonville | Florida | 32216 | — |
| Pfizer Investigational Site | Miami | Florida | 33156 | — |
| Pfizer Investigational Site | West Palm Beach | Florida | 33401 | — |
| Pfizer Investigational Site | Winter Park | Florida | 32789 | — |
| Pfizer Investigational Site | Columbus | Georgia | 31904 | — |
| Pfizer Investigational Site | Decatur | Georgia | 30034-1680 | — |
| Pfizer Investigational Site | Honolulu | Hawaii | 96813 | — |
| Pfizer Investigational Site | Honululu | Hawaii | 96814 | — |
| Pfizer Investigational Site | Idaho Falls | Idaho | 83404 | — |
| Pfizer Investigational Site | Chicago | Illinois | 60607 | — |
| Pfizer Investigational Site | Gurnee | Illinois | 60031 | — |
| Pfizer Investigational Site | Des Moines | Iowa | 50314 | — |
| Pfizer Investigational Site | Lexington | Kentucky | 40503 | — |
| Pfizer Investigational Site | Louisville | Kentucky | 40213 | — |
| Pfizer Investigational Site | Baltimore | Maryland | 21234-4607 | — |
| Pfizer Investigational Site | Bethesda | Maryland | 20817 | — |
| Pfizer Investigational Site | Boston | Massachusetts | 02114 | — |
| Pfizer Investigational Site | Flint | Michigan | 48532 | — |
| Pfizer Investigational Site | Minneapolis | Minnesota | 55454-1321 | — |
| Pfizer Investigational Site | St Louis | Missouri | 63110 | — |
| Pfizer Investigational Site | St Louis | Missouri | 63141 | — |
| Pfizer Investigational Site | Omaha | Nebraska | 68131 | — |
| Pfizer Investigational Site | East Syracuse | New York | 13057 | — |
| Pfizer Investigational Site | Greenville | North Carolina | 27834 | — |
| Pfizer Investigational Site | Morehead City | North Carolina | 28557 | — |
| Pfizer Investigational Site | Statesville | North Carolina | 28625 | — |
| Pfizer Investigational Site | Kettering | Ohio | 45429 | — |
| Pfizer Investigational Site | Oklahoma City | Oklahoma | 73103 | — |
| Pfizer Investigational Site | Tulsa | Oklahoma | 74104 | — |
| Pfizer Investigational Site | Bend | Oregon | 97701 | — |
| Pfizer Investigational Site | Bensalem | Pennsylvania | 19020 | — |
| Pfizer Investigational Site | Greenville | South Carolina | 29615 | — |
| Pfizer Investigational Site | Bartlett | Tennessee | 38133 | — |
| Pfizer Investigational Site | Memphis | Tennessee | 38119 | — |
| Pfizer Investigational Site | Arlington | Texas | 76012 | — |
| Pfizer Investigational Site | Arlington | Texas | 76014 | — |
| Pfizer Investigational Site | Dallas | Texas | 75230 | — |
| Pfizer Investigational Site | Dallas | Texas | 75246 | — |
| Pfizer Investigational Site | El Paso | Texas | 79935 | — |
| Pfizer Investigational Site | Houston | Texas | 77004 | — |
| Pfizer Investigational Site | San Antonio | Texas | 78229 | — |
| Pfizer Investigational Site | Bennington | Vermont | 05201-5018 | — |
| Pfizer Investigational Site | Norfolk | Virginia | 23502 | — |
| Pfizer Investigational Site | Virginia Beach | Virginia | 23462 | — |
| Pfizer Investigational Site | Renton | Washington | 98055 | — |
| Pfizer Investigational Site | Spokane | Washington | 99208 | — |
| Pfizer Investigational Site | Milwaukee | Wisconsin | 53209 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
Recently updated Diabetes Mellitus trials
Other public records listing Diabetes Mellitus. Sorted by last update posted; newest first. Not a recommendation.
- NCT05415878: Impact of Removable Cast Walker Design on Usability for Patients With Diabetic Foot Ulcers Recruiting
- NCT04055428: NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals Recruiting
- NCT06337708: Smart Walk: A Culturally Tailored Smartphone-Delivered Physical Activity Intervention for African American Women Recruiting
- NCT07006480: Inpatient Use of Personal Continuous Glucose Monitor (CGM) to Improve Diabetes Mellitus Control Recruiting
- NCT03655223: Early Check: Expanded Screening in Newborns Active, not recruiting
- NCT05866536: Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00348374, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 15, 2010 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00348374 live on ClinicalTrials.gov.